{
    "organizations": [],
    "uuid": "388baa53902b0ff9f57c9a70d5b44702f9a6540f",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-puma-biotechnology-and-canbridge-l/brief-puma-biotechnology-and-canbridge-life-sciences-enter-into-exclusive-licensing-agreement-to-commercialize-nerlynx-in-greater-china-idUSFWN1PR1BD",
    "ord_in_thread": 0,
    "title": "BRIEF-Puma Biotechnology And Canbridge Life Sciences Enter Into Exclusive Licensing Agreement To Commercialize Nerlynx In Greater China",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Feb 1 (Reuters) - Puma Biotechnology Inc:\n* PUMA BIOTECHNOLOGY AND CANBRIDGE LIFE SCIENCES ENTER INTO EXCLUSIVE LICENSING AGREEMENT TO COMMERCIALIZE NERLYNXÂ® (NERATINIB) IN GREATER CHINA Source text for Eikon: Further company coverage:\n ",
    "published": "2018-02-02T06:26:00.000+02:00",
    "crawled": "2018-02-02T12:37:31.000+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "feb",
        "reuters",
        "puma",
        "biotechnology",
        "inc",
        "puma",
        "biotechnology",
        "canbridge",
        "life",
        "science",
        "enter",
        "exclusive",
        "licensing",
        "agreement",
        "commercialize",
        "neratinib",
        "greater",
        "china",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}